Related references
Note: Only part of the references are listed.AmpC induction by ceftaroline
Shazad Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Activity of chequerboard combinations of ceftaroline and NXL104 versus β-lactamase-producing Enterobacteriaceae
S. Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity
George L. Drusano
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
In Vitro Activity of NXL104 in Combination with β-Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases
Andrea Endimiani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
Therese Stachyra et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria
Patrice Nordmann et al.
LANCET INFECTIOUS DISEASES (2009)
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States
Yigong Ge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Resistant gram-negative bacilli: A neglected healthcare crisis?
Ebbing Lautenbach et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2007)
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes
Shazad Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore
Paul G. Ambrose et al.
CLINICAL INFECTIOUS DISEASES (2007)
Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models:: Identification of an in vivo pharmacokinetic-pharmacodynamic target
D Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Application of antimicrobial pharmacodynamic concepts into clinical practice: Focus on beta-lactam antibiotics - Insights from the society of infectious diseases pharmacists
Thomas P. Lodise et al.
PHARMACOTHERAPY (2006)
Optimising dosing strategies of antibacterials utilising pharmacodynamic principles - Impact on the development of resistance
CA DeRyke et al.
DRUGS (2006)
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains
HS Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'
GL Drusano
NATURE REVIEWS MICROBIOLOGY (2004)
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004
D Cardo et al.
AMERICAN JOURNAL OF INFECTION CONTROL (2004)
TAK-599, a novel N-phosphono type prodrug of Anti-MRSA cephalosporin T-91825:: Synthesis, physicochemical and pharmacological properties
T Ishikawa et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2003)
Share Paper
